MedTrace Logo

Real-world Effectiveness and Cost-effectiveness of Leading Inhaled Corticosteroids in Asthma Management

NCT01141439 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 815377

Last updated 2013-03-14

No results posted yet for this study

Summary

The objective of the study was to compare the effectiveness, cost-effectiveness and direct healthcare costs of managing asthma in patients with evidence of persistent asthma, following the initiation and increased dose of inhaled corticosteroid (ICS) therapy using HFA-BDP (Qvar®) (either as initial therapy or as a step-up therapy) compared with the most commonly prescribed alternative ICS in the UK, CFC-beclometasone (BDP) and fluticasone (FP) as metered dose inhalers (MDIs). Qvar vs FP analyses were split between adults (12-60yrs) and paediatrics (5-11yrs).

Conditions

Interventions

DRUG

Extra-fine hydrofluoroalkane-beclomethasone dipropionate

Initiation of HFA-BDP (any dose) in steroid naive patients via MDI

DRUG

Extra-fine hydrofluoroalkane-beclomethasone dipropionate

An increase in the baseline BDP-equivalent dose of inhaled corticosteroid as HFA-BDP via MDI

DRUG

Fluticasone propionate

An increase in the baseline BDP-equivalent dose of inhaled corticosteroid as FP via MDI

DRUG

Beclomethasone dipropionate

An increase in the baseline BDP-equivalent dose of inhaled corticosteroid as CFC-BDP via MDI

DRUG

fluticasone propionate

Initiation of FP (any dose) via MDI in steroid naive patient

DRUG

Chlorofluorocarbon beclomethasone dipropionate

Initiation of CFC-BDP (any dose) via MDI in steroid naive patient

Sponsors & Collaborators

  • Teva Branded Pharmaceutical Products R&D, Inc.

    collaborator INDUSTRY

  • Research in Real-Life Ltd

    lead NETWORK

Principal Investigators

  • David Price, Prof. MD · Company Director

  • Alison Chisholm, MSc · Research Project Director

Eligibility

Min Age
5 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-01-31
Primary Completion
2007-06-30
Completion
2010-07-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01141439 on ClinicalTrials.gov